313 related articles for article (PubMed ID: 26352769)
21. ROS1 [corrected].
Pal P; Khan Z
J Clin Pathol; 2017 Dec; 70(12):1001-1009. PubMed ID: 28903995
[TBL] [Abstract][Full Text] [Related]
22. [Personalized medicine in non-small-cell carcinoma].
Iwama E; Takayama K; Baba E; Nakanishi Y
Fukuoka Igaku Zasshi; 2014 Mar; 105(3):57-66. PubMed ID: 25000657
[No Abstract] [Full Text] [Related]
23. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
[TBL] [Abstract][Full Text] [Related]
24. Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients.
Juan O; Popat S
Lung Cancer; 2017 Feb; 104():131-133. PubMed ID: 27863911
[No Abstract] [Full Text] [Related]
25. ROS1-targeted therapy in non-small cell lung cancer.
Sequist LV
Clin Adv Hematol Oncol; 2012 Dec; 10(12):827-8. PubMed ID: 23271356
[No Abstract] [Full Text] [Related]
26. [Treatment of advanced non-small-cell lung cancer with driver mutations].
Tessmer A; Kollmeier J
Dtsch Med Wochenschr; 2015 Mar; 140(5):323-8. PubMed ID: 25734673
[TBL] [Abstract][Full Text] [Related]
27. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.
Davare MA; Vellore NA; Wagner JP; Eide CA; Goodman JR; Drilon A; Deininger MW; O'Hare T; Druker BJ
Proc Natl Acad Sci U S A; 2015 Sep; 112(39):E5381-90. PubMed ID: 26372962
[TBL] [Abstract][Full Text] [Related]
28. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
Loong HH; Mok K; Leung LK; Mok TS
Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
[TBL] [Abstract][Full Text] [Related]
29. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation.
Lee JK; Kim TM; Koh Y; Lee SH; Kim DW; Jeon YK; Chung DH; Yang SC; Kim YT; Kim YW; Heo DS; Bang YJ
Lung Cancer; 2012 Aug; 77(2):460-3. PubMed ID: 22622260
[TBL] [Abstract][Full Text] [Related]
30. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.
Song A; Kim TM; Kim DW; Kim S; Keam B; Lee SH; Heo DS
Clin Cancer Res; 2015 May; 21(10):2379-87. PubMed ID: 25688157
[TBL] [Abstract][Full Text] [Related]
31. Patient-derived models of acquired resistance can identify effective drug combinations for cancer.
Crystal AS; Shaw AT; Sequist LV; Friboulet L; Niederst MJ; Lockerman EL; Frias RL; Gainor JF; Amzallag A; Greninger P; Lee D; Kalsy A; Gomez-Caraballo M; Elamine L; Howe E; Hur W; Lifshits E; Robinson HE; Katayama R; Faber AC; Awad MM; Ramaswamy S; Mino-Kenudson M; Iafrate AJ; Benes CH; Engelman JA
Science; 2014 Dec; 346(6216):1480-6. PubMed ID: 25394791
[TBL] [Abstract][Full Text] [Related]
32. Personalized therapy for lung cancer: striking a moving target.
Pakkala S; Ramalingam SS
JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089719
[TBL] [Abstract][Full Text] [Related]
33. Dual potent ALK and ROS1 inhibitors combating drug-resistant mutants: Synthesis and biological evaluation of aminopyridine-containing diarylaminopyrimidine derivatives.
Guo M; Zuo D; Zhang J; Xing L; Gou W; Jiang F; Jiang N; Zhang D; Zhai X
Eur J Med Chem; 2018 Oct; 158():322-333. PubMed ID: 30223120
[TBL] [Abstract][Full Text] [Related]
34. Bronchoscopic Re-biopsy for Mutational Analysis of Non-small Cell Lung Cancer.
Kirita K; Izumo T; Matsumoto Y; Hiraishi Y; Tsuchida T
Lung; 2016 Jun; 194(3):371-8. PubMed ID: 26951235
[TBL] [Abstract][Full Text] [Related]
35. Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development.
Wijesinghe P; Bollig-Fischer A
Adv Exp Med Biol; 2016; 890():1-23. PubMed ID: 26703796
[TBL] [Abstract][Full Text] [Related]
36. ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway.
Ou SH; Tan J; Yen Y; Soo RA
Expert Rev Anticancer Ther; 2012 Apr; 12(4):447-56. PubMed ID: 22500682
[TBL] [Abstract][Full Text] [Related]
37. ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis.
Ahn HK; Han B; Lee SJ; Lim T; Sun JM; Ahn JS; Ahn MJ; Park K
Lung Cancer; 2012 May; 76(2):253-4. PubMed ID: 22385925
[TBL] [Abstract][Full Text] [Related]
38. The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer.
Kaczmar J; Mehra R
Ther Adv Respir Dis; 2015 Oct; 9(5):236-41. PubMed ID: 26229087
[TBL] [Abstract][Full Text] [Related]
39. New and emerging targeted treatments in advanced non-small-cell lung cancer.
Hirsch FR; Suda K; Wiens J; Bunn PA
Lancet; 2016 Sep; 388(10048):1012-24. PubMed ID: 27598681
[TBL] [Abstract][Full Text] [Related]
40. ROS1-rearranged Non-small Cell Lung Cancer.
Giustini NP; Bazhenova L
Thorac Surg Clin; 2020 May; 30(2):147-156. PubMed ID: 32327173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]